Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects

Background: despite well-studied safety profile of dabigatran its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD). This study was aimed to evaluate relationships between CES1 and ABCB1 polymorphism, dabigatran...

全面介紹

書目詳細資料

發表在:	Медицинский совет
Main Authors:	A. I. Skripka, P. O. Bochkov, K. A. Akmalova, R. V. Shevchenko, P. M. Krupenin, V. V. Kogay, A. I. Listratov, A. S. Krainyaya, D. A. Napalkov, O. S. Gurinovich, A. A. Sokolova, V. V. Fomin, D. A. Sychev
格式:	Article
語言:	俄语
出版:	Remedium Group LLC 2020-01-01
主題:	doac dabigatran atrial fibrillation chronic kidney disease hemorrhagic events abcb1 ces1 rs1045642 rs2244613 rs4148738 pharmacokinetics pharmacogenetics
在線閱讀:	https://www.med-sovet.pro/jour/article/view/5476